ARROWHEAD PHARMACEUTICALS Reports 51.2% Decrease in Total Revenue for Third Quarter of FY2023
August 12, 2023
🌥️Earnings Overview
ARROWHEAD PHARMACEUTICALS ($NASDAQ:ARWR) announced their earnings results for the third quarter of FY2023 on August 7 2023, with total revenue reported at USD 15.8 million, which was a 51.2% decrease from the same quarter in the prior year. Their net income was -103.0 million, compared to -72.0 million in the year before.
Analysis
GoodWhale allows investors to analyze the fundamentals of ARROWHEAD PHARMACEUTICALS in order to make an informed investment decision. According to GoodWhale’s risk rating system, ARROWHEAD PHARMACEUTICALS is a medium risk investment in terms of financial and business aspects. GoodWhale also has detected 2 risk warnings in the company’s income sheet and cashflow statement. To gain access to this important information, investors must register with GoodWhale. By doing so, investors can gain valuable insights into ARROWHEAD PHARMACEUTICALS’ financial stability and have more confidence in their investing decisions. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Arrowhead Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 256.21 | -181.11 | -70.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Arrowhead Pharmaceuticals. More…
| Operations | Investing | Financing |
| -197.37 | -90.22 | 253.76 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Arrowhead Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 795.86 | 413.87 | 3.41 |
Key Ratios Snapshot
Some of the financial key ratios for Arrowhead Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 27.5% | – | -67.3% |
| FCF Margin | ROE | ROA |
| -133.8% | -26.6% | -13.5% |
Peers
It also has a large marketing and sales force that helps it to sell its products to customers.
– Lin BioScience Inc ($TPEX:6696)
Sangamo Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel genomic therapies. The Company’s technology platform is based on zinc finger DNA-binding proteins (ZFPs). The Company’s product candidates are designed to target and modulate the activity of specific genes associated with disease. The Company’s lead product candidates include SB-525, which is in Phase III clinical trials for the treatment of hemophilia A, and SB-913, which is in Phase I/II clinical trials for the treatment of Mucopolysaccharidosis Type I (MPS I).
– Acer Therapeutics Inc ($NASDAQ:ACER)
Acer Therapeutics Inc is a pharmaceutical company that focuses on the development and commercialization of therapies for serious rare and life-threatening diseases. The company’s lead product candidate, Etrasimod, is in clinical development for the treatment of ulcerative colitis, Crohn’s disease, and relapsing multiple sclerosis. Acer also has a portfolio of product candidates in various stages of development for the treatment of rare genetic disorders, including Duchenne muscular dystrophy, Friedreich’s ataxia, alpha-1 antitrypsin deficiency, and Gaucher disease.
– Innovation1 Biotech Inc ($OTCPK:IVBT)
Innovation1 Biotech Inc is a company that focuses on developing innovative treatments for diseases. The company has a market cap of 1.6M as of 2022 and a Return on Equity of -5.58%. The company’s market cap is the value of its outstanding shares of stock. The company’s ROE is a measure of how much profit it generates for shareholders.
Summary
ARROWHEAD PHARMACEUTICALS released third quarter results for fiscal 2023, which showed a significant decrease in revenue compared to the same quarter in the previous year. Revenue dropped by 51.2% to USD 15.8 million, and net income was reported to be -103.0 million. This is a stark contrast to the prior year, where net income was -72.0 million.
Investors should exercise caution when considering investing in ARROWHEAD PHARMACEUTICALS as the company’s financials seem to be declining. Further research is recommended before making any decisions.
Related Posts
Recent Posts
